Laser-Assisted Drug Delivery
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Jill S. Waibel, subsection chief of dermatology at Baptist Hospital of Miami, medical director of the Miami Cancer Institute’s Multispecialty Skin Cancer Clinic, and assistant voluntary professor at the University of Miami Miller School of Medicine. Learn about the emerging field of laser-assisted dru …
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Jill S. Waibel, subsection chief of dermatology at Baptist Hospital of Miami, medical director of the Miami Cancer Institute’s Multispecialty Skin Cancer Clinic, and assistant voluntary professor at the University of Miami Miller School of Medicine. Learn about the emerging field of laser-assisted dru … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, interviewed Dr. Iltefat Hamzavi, a dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Learn from Dr. Hamzavi the key pillars of vitiligo treatment, and why there’s room to improve available options for melanocyte recruitment and repair. Dr. Hamza … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, interviewed Dr. Heather Woolery-Lloyd, director of the Skin of Color Division for the University of Miami Department of Dermatology. Watch as Dr. Woolery-Lloyd outlines the role of superficial chemical peels in treating pigmentary disorders. Learn how chemical peels impact other treatments. Find out her chemical peel … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Amit Pandya, staff dermatologist with Palo Alto Foundation Medical Group and adjunct professor in the department of dermatology at the University of Texas Southwestern Medical Center. Dr. Pandya says this is the most exciting time for him as a dermatologist with new vitiligo medications on the market an … 